What is Leerink Partnrs’ Forecast for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Wave Life Sciences in a report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.12) EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The firm had revenue of $83.75 million for the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Jefferies Financial Group started coverage on Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target for the company. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Wave Life Sciences Stock Down 4.2 %

Shares of NASDAQ:WVE opened at $7.74 on Monday. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.97 and a beta of -1.04. The stock’s 50 day moving average is $10.61 and its 200-day moving average is $11.75.

Insider Transactions at Wave Life Sciences

In related news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 29.10% of the company’s stock.

Institutional Investors Weigh In On Wave Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Wave Life Sciences by 209.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock valued at $6,926,000 after buying an additional 571,345 shares in the last quarter. FMR LLC raised its stake in shares of Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after purchasing an additional 979,110 shares during the period. Maven Securities LTD purchased a new stake in Wave Life Sciences during the 3rd quarter worth about $6,970,000. Barclays PLC boosted its stake in Wave Life Sciences by 171.1% in the 3rd quarter. Barclays PLC now owns 159,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 100,498 shares during the period. Finally, Cinctive Capital Management LP boosted its position in shares of Wave Life Sciences by 255.7% in the third quarter. Cinctive Capital Management LP now owns 356,308 shares of the company’s stock valued at $2,922,000 after acquiring an additional 256,146 shares during the period. 89.73% of the stock is currently owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.